ACR 2025 experts explore gout’s deep ties to MetS, insulin resistance & cardiovascular mortality, weighing new data on colchicine, febuxostat & SGLT2 inhibitors.
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
FDA Approves 2 More Denosumab Biosimilars
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
The 2025 ACR Awards of Distinction
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
The 2025 ARP President’s & Merit Awards
Meet the 2025 ARP President’s & Merit Award recipients honored for their significant contributions to rheumatology research, education & patient care.
The ACR Names 16 New Masters
The ACR recognizes 16 members with its highest honor. See the 2025 class of ACR Masters & read their personal reflections on this career milestone.
ACR Honors Distinguished Fellows: Class of 2025
Meet the 10 clinical & research fellows named 2025 ACR Distinguished Fellows. Learn what this prestigious honor means to them & their work.
The Rheum Advocate: A Fresh Look for the Same Trusted Voice
Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.
ACR Delegation to Address AI, Non-Compete Agreements at Interim AMA House of Delegates Meeting
The ACR’s resolutions at the Interim HOD meeting, held Nov. 14–18, will address non-compete agreements as well as the use of artificial intelligence (AI) in prior authorization processes.
- 1
- 2
- 3
- …
- 834
- Next Page »